Form 4: Acumen Pharma CDO Sells Shares for Tax Obligations

Acumen Pharmaceuticals' President and CDO, James J. Doherty, sold common stock totaling 8,167 shares over two days to cover tax withholding obligations from RSU vesting.

Summary

• James J. Doherty, President and CDO of Acumen Pharmaceuticals, Inc. (ABOS), reported sales of common stock.
• On January 7, 2026, Doherty sold 1,700 shares at a weighted average price of $1.9879 per share, with prices ranging from $1.9550 to $2.0200.
• On January 8, 2026, Doherty sold an additional 6,467 shares at a weighted average price of $1.8198 per share, with prices ranging from $1.7200 to $1.9500.
• These sales were 'sell to cover' transactions to satisfy tax withholding obligations related to the vesting of restricted stock units (RSUs).
• The transactions were executed under a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2025.
• Following the January 8, 2026 transaction, Doherty beneficially owns 54,033 shares of common stock.
• The filing also corrected a typographical error from a previous Form 4 report filed January 7, 2025, which had overreported RSU grants on January 6, 2025, by 400 shares.

Sentiment

Score: 5

Explanation: Neutral. The sales are routine 'sell to cover' transactions for tax purposes under a pre-arranged plan, which is a common and expected event for executives receiving equity compensation. It does not reflect a change in management's outlook on the company or its future prospects.

Positives

• Transactions were pre-planned under a Rule 10b5-1 plan, indicating non-discretionary sales for tax purposes rather than a change in sentiment regarding the company's prospects.
• The correction of a previous reporting error demonstrates a commitment to accurate disclosure and regulatory compliance.

Negatives

• Insider selling, even for tax purposes, reduces the insider's direct equity stake in the company.
• The sales occurred at prices below $2.00, which might be perceived negatively if the stock has been trading higher or if investors are sensitive to price points.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing, as it primarily reports past insider transactions.

Industry Context

This filing reports routine insider transactions, specifically 'sell to cover' sales for tax obligations, which are common occurrences for executives across all industries who receive equity compensation. The use of a Rule 10b5-1 plan is a standard practice to manage such sales in a compliant and transparent manner.

Comparison to Industry Standards

• The execution of 'sell to cover' transactions to satisfy tax withholding obligations upon RSU vesting is a standard and widely accepted practice for executives receiving equity compensation in publicly traded companies.
• The adoption of a Rule 10b5-1 trading plan, as noted for James J. Doherty on September 30, 2025, aligns with best practices in corporate governance to demonstrate that insider sales are pre-planned and not based on material non-public information, a common standard across the industry.

Corporate Governance

Stakeholder Impact

• Shareholders: The sale of shares by an executive, even for tax purposes, results in a minor reduction of insider ownership. However, the pre-planned nature under a Rule 10b5-1 plan typically minimizes negative sentiment. The correction of a previous reporting error improves data accuracy for investors.
• Employees: No direct impact on employees is mentioned in this transactional filing.

Key Dates

Recommendation

The filing details routine 'sell to cover' transactions by an executive to satisfy tax obligations related to RSU vesting, executed under a pre-arranged Rule 10b5-1 plan. This is a common and expected event for executives receiving equity compensation and does not typically signal a change in the company's fundamentals or management's outlook. Therefore, it provides no new information that would warrant a change in investment recommendation, suggesting a 'hold' position is appropriate based solely on this filing.

Keywords

Acumen Pharmaceuticals, ABOS, Form 4, Insider Trading, Stock Sale, Restricted Stock Units, RSU, Tax Withholding, Rule 10b5-1, James J. Doherty, Officer Transaction